Shingo Narita
Postdoctoral Scholar, Cardiovascular Institute
Bio
Postdoctoral Fellow
Cardiologist (Japan)
Research expertise: AL amyloid cardiomyopathy, Cardiac regeneration
Boards, Advisory Committees, Professional Organizations
-
Board Certified Physician of Japanese Society of Internal Medicine, Japanese Society of Internal Medicine (2014 - Present)
-
Board Certified Cardiologist of Japanese Circulation Society, Japanese Circulation Society (2019 - Present)
-
Board Certified Physician of Japanese Association of Cardiovascular Intervention and Therapeutics, Japanese Association of Cardiovascular Intervention and Therapeutics (2021 - Present)
Professional Education
-
Doctor of Philosophy, Nagoya University Intl Program (2023)
-
Doctor of Medicine, Hokkaido University (2010)
-
PhD, Nagoya University Graduate School of Medicine (2023)
-
MD, Hokkaido University (2010)
All Publications
-
Dynamic upregulation of retinoic acid signal in the early postnatal murine heart promotes cardiomyocyte cell cycle exit and maturation.
Scientific reports
2024; 14 (1): 20222
Abstract
The adult mammalian heart has extremely limited cardiac regenerative capacity. Most cardiomyocytes live in a state of permanent cell-cycle arrest and are unable to re-enter the cycle. Cardiomyocytes switch from cell proliferation to a maturation state during neonatal development. Although several signaling pathways are involved in this transition, the molecular mechanisms by which these inputs coordinately regulate cardiomyocyte maturation are not fully understood. Retinoic acid (RA) plays a pivotal role in development, morphogenesis, and regeneration. Despite the importance of RA signaling in embryo heart development, little is known about its function in the early postnatal period. We found that mRNA expression of aldehyde dehydrogenase 1 family member A2 (Aldh1a2), which encodes the key enzyme for synthesizingall-trans retinoic acid (ATRA) and is an important regulator for RA signaling, was transiently upregulated in neonatal mouse ventricles. Single-cell transcriptome analysis and immunohistochemistry revealed that Aldh1a2 expression was enriched in cardiac fibroblasts during the early postnatal period. Administration of ATRA inhibited cardiomyocyte proliferation in cultured neonatal rat cardiomyocytes and human cardiomyocytes. RNA-seq analysis indicated that cell proliferation-related genes were downregulated in prenatal rat ventricular cardiomyocytes treated with ATRA, while cardiomyocyte maturation-related genes were upregulated. These findings suggest that RA signaling derived from cardiac fibroblasts is one of the key regulators of cardiomyocyte proliferation and maturation during neonatal heart development.
View details for DOI 10.1038/s41598-024-70918-1
View details for PubMedID 39215116
-
Direct reprogramming of adult adipose-derived regenerative cells toward cardiomyocytes using six transcriptional factors.
iScience
2022; 25 (7): 104651
Abstract
It is widely accepted that adipose-derived regenerative cells (ADRCs) can differentiate into mesodermal lineage cells. However, reprogramming adult ADRCs into mature cardiomyocytes is challenging. We investigated the induction of myocardial differentiation in ADRCs via direct reprogramming using lentiviral gene transfer. First, we identified candidate transcriptional factors by performing RNA sequencing and ultimately confirmed that the combination of six unique factors (Baf60c, Gata4, Gata6, Klf15, Mef2a, and Myocd) could efficiently express enhanced green fluorescent protein (GFP) in ADRCs isolated from adult alpha-myosin heavy chain promoter-driven GFP transgenic mice. The GFP-positive ADRCs induced by six factors (6F-ADRCs) expressed multiple cardiac genes and revealed cardiac differentiation in bioinformatic analysis. Moreover, injection of 6F-ADRCs into acute myocardial infarcted tissues in vivo resulted in the improvement of survival rate, fractional shortening, and reduction of infarction scar area. This study provides an alternative method for direct reprogramming of adult ADRCs into cardiomyocytes.
View details for DOI 10.1016/j.isci.2022.104651
View details for PubMedID 35811849
View details for PubMedCentralID PMC9263527